Global CRO footprint RoukenBio has a growing international presence with customers in over 27 countries and recent expansion of discovery facilities in the United Kingdom and Northern Europe, signaling readiness to support larger, cross-border partnerships and multi-region studies.

Diverse therapeutic focus Capabilities span inflammation, auto-immunity, immuno-oncology, oncology and emerging modalities including antibodies, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines and ADCs, presenting multiple entry points for collaboration across early discovery to GMP-ready assays.

IndEx-2 platform Unique inducible cell line platform IndEx-2 highlights RoukenBio’s differentiating technology that enables disease-state modelling, offering potential for bespoke assays and accelerated pathway to IND-enabling data for clients.

Collaborative model Emphasis on thought-partner research collaborations and personalised CRO services suggests opportunities for co-development programs, flexible engagement models, and expanded scope beyond traditional CRO deliverables.

Growth signals Mid-market scale with 51-200 employees and revenue in the low-to-mid multi-million range, coupled with recent facility expansion, indicates capacity to scale collaborations, propose tiered service packages, and target mid-sized biotechs seeking hands-on CRO partnerships.